People: Dynavax Technologies Corp (DVAX.W)
DVAX.W on CBOE When Trading NASDAQ Global Select Market
2.50USD
22 May 2013
2.50USD
22 May 2013
Price Change (% chg)
$-0.01 (-0.40%)
$-0.01 (-0.40%)
Prev Close
$2.51
$2.51
Open
$2.57
$2.57
Day's High
$2.58
$2.58
Day's Low
$2.48
$2.48
Volume
4,118
4,118
Avg. Vol
12,080
12,080
52-wk High
$5.07
$5.07
52-wk Low
$1.75
$1.75
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
Arnold Oronsky |
73 | 2006 | Independent Chairman of the Board |
J. Tyler Martin |
2010 | President, Chief Medical Officer, Director | |
Eddie Gray |
2013 | Chief Executive Officer, Director | |
Zbigniew Janowicz |
61 | 2006 | Chief Executive Officer, Managing Director of Rhein Biotech GmbH (Dynavax Europe) |
David Novack |
50 | 2013 | Senior Vice President - Operations and Quality |
Jennifer Lew |
39 | 2009 | Vice President - Finance, Principal Accounting Officer |
Robert Coffman |
65 | 2000 | Vice President, Chief Scientific Officer |
Michael Ostrach |
60 | 2006 | Vice President, Chief Business Officer, General Counsel |
David Happel |
2012 | Vice President - Global Sales and Marketing | |
Dino Dina |
2013 | Director | |
Francis Cano |
65 | 2009 | Independent Director |
Dennis Carson |
65 | 1997 | Independent Director |
Denise Gilbert |
54 | 2004 | Independent Director |
Daniel Kisner |
65 | 2010 | Independent Director |
Peggy Phillips |
58 | 2006 | Independent Director |
Stanley Plotkin |
79 | 2005 | Independent Director |
Biographies
| Name | Description |
|---|---|
Arnold Oronsky |
Dr. Arnold L. Oronsky, Ph.D., serves as an Independent Chairman of the Board of Dvnavax Technologies Corporation. He has been a member of Board since November 1996 and became Chairman in February 2006. Dr. Oronsky is a managing director with InterWest Partners, a venture capital firm. Prior to joining InterWest Partners in 1994, Dr. Oronsky was Vice President of Discovery Research for the Lederle Laboratories division of American Cyanamid, a pharmaceutical company. From 1973 until 1976, Dr. Oronsky was head of the inflammation, allergy and immunology research program at Ciba-Geigy Pharmaceutical Company. Dr. Oronsky also serves as a senior lecturer in the Department of Medicine at The Johns Hopkins Medical School. Dr. Oronsky has won numerous grants and awards and has published over 125 scientific articles. Dr. Oronsky served on the board of directors of Anesiva, Inc. from 2005 to 2010. Anesiva filed a voluntary petition for relief under Chapter 7 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the Northern District of California in January 2010. He received his Ph.D. from Columbia University, College of Physicians and Surgeons and his A.B. from New York University. |
J. Tyler Martin |
Dr. J. Tyler Martin, M.D., was President, Chief Medical Officer and Director of Dynavax Technologies Corporation. Dr. Martin joined Dynavax in February 2009 as Chief Medical Officer and was appointed as the Company’s President and to the Board in July 2010. Dr. Martin has 20 years of drug development experience. From 2007 to 2008, Dr. Martin was President of Humabs Llc. Previously, Dr. Martin worked at Chiron Corporation, a biopharmaceutical company, as the Vice President, Development from 2004 until 2006 and the Director, Clinical Research from 1994 until 1997. In his seven years at Chiron, Dr. Martin led the team responsible for the development of the novel vaccine adjuvant MF59, the first vaccine adjuvant licensed by regulatory agencies since alum, and approved as FLUAD influenza vaccine in Europe. He has also held senior development and research positions at Sangamo, Inc., Valentis, Inc. and SyStemix/GTI. Dr. Martin received a B.S. in Chemistry and an M.D. from the University of Nebraska. He completed his fellowship in pediatric infectious diseases and molecular microbiology at Washington University in St. Louis, Missouri. |
Eddie Gray |
Mr. Eddie Gray is Chief Executive Officer, Director of Dynavax Technologies Corporation. Most recently, Mr. Gray served as the President of Pharmaceuticals Europe at GlaxoSmithKline plc (GSK) since 2008 and as Senior Vice President and General Manager of Pharmaceuticals UK from 2001 through 2007. In both roles, he was instrumental in the launch, commercialization and strategic development of GSK's vaccine portfolio. Prior to the formation of GSK, Mr. Gray was with SmithKline Beecham from 1988 through 2000 serving in various positions of increasing responsibility, including Vice President and Director of Anti-Infectives Marketing in the US, Vice President and Director of the Vaccines Business Unit in the US, and Vice President and General Manager of Pharmaceuticals in Canada. Mr. Gray received a Bachelor of Science degree in Chemistry and Management Studies from the University of London and an MBA from the Cranfield School of Management in the UK. |
Zbigniew Janowicz |
Dr. Zbigniew Janowicz, Ph.D., serves as Chief Executive Officer and Managing Director of Rhein Biotech GmbH (Dynavax Europe) of Dynavax Technologies Corporation. Dr. Janowicz joined Dynavax in April 2006 when Dynavax acquired Rhein Biotech GmbH, or Dynavax Europe. In July 2006, Dr. Janowicz was appointed Chief Executive Officer of Dynavax Europe. Dr. Janowicz holds a Ph.D. in Biochemistry. He was one of the co-founders of Rhein Biotech GmbH in 1985 and laid the foundation for the development and commercialization of the Hansenula polymorpha technology platform used in the production of vaccine antigens and other proteins. He also led the development of the hepatitis B franchise of the Rhein Biotech GmbH group. From 1996 until 1999, Dr. Janowicz served as R&D Director in the tissue repair business of Curative Technologies. He rejoined Rhein Biotech GmbH in 1999 where he held the position of R&D Director for the Rhein Biotech Group. |
David Novack |
Mr. David Novack has been appointed as Senior Vice President - Operations and Quality of Dynavax Technologies Corporation effective March 25, 2013. He is joining Dynavax from Novartis Vaccines & Diagnostics where he served since 2009 as the Global Head of Technical Operations and Supply Chain for Diagnostics and previously from 2007 to 2009 as the Global Head of Vaccine Manufacturing Strategy. Prior to Novartis, Mr. Novack was the Vice President, Business Development for Vaxin, Inc., a vaccine company, from 2004 to 2006. From 1993 until 2004, Mr. Novack worked at MedImmune, formerly Aviron, serving in several capacities including business development, manufacturing, contract operations and most recently as Senior Director, Supply Chain Operations. Previously, from 1989 to 1993, Mr. Novack was with American Cyanamid Company in various roles. Mr. Novack received a B.S. in Biology from State University of New York and an M.B.A. from Columbia University. |
Jennifer Lew |
Ms. Jennifer Lew, CPA., serves as Vice President - Finance, Principal Accounting Officer of Dynavax Technologies Corporation. Ms. Lew joined Dynavax in December 2004 and is the Company’s Vice President, Finance and Principal Accounting Officer. Ms. Lew previously served as Senior Director and Corporate Controller for Dynavax. Prior to joining the Company, Ms. Lew was with QRS Corporation, an e-commerce provider for the retail industry, as Assistant Controller from 2002 until 2004 and Director of Finance from 2000 until 2002. From 1994 to 1999, Ms. Lew worked for Ernst & Young, most recently as Manager. She earned a B.A. in Economics/Accounting and Government from Claremont McKenna College and is a Certified Public Accountant (inactive). |
Robert Coffman |
Dr. Robert L. Coffman, Ph.D., serves as Vice President and Chief Scientific Officer of Dynavax Technologies Corporation since December 2000. Dr. Coffman has been Vice President and Chief Scientific Officer since December 2000. Dr. Coffman joined Dynavax from the DNAX Research Institute where he had been since 1981, most recently as Distinguished Research Fellow. Prior to that, he was a postdoctoral fellow at Stanford University Medical School. Dr. Coffman has made fundamental discoveries about the regulation of immune responses in allergic and infectious diseases. He shared the William S. Coley Award for Research in Immunology for discovery of the Th1 and Th2 subsets of T lymphocytes, the two types of T cells that control most immune responses. Dr. Coffman received his Ph.D. from the University of California, San Diego and his A.B. from Indiana University. In 2006, Dr. Coffman was elected to the National Academy of Sciences. Since May 2011, Dr. Coffman has provided advisory services to the Baylor Research Institute. |
Michael Ostrach |
Mr. Michael S. Ostrach serves as Vice President, Chief Business Officer and General Counsel of Dynavax Technologies Corporation since October 31, 2006. From 2005 to 2006, he was Chief Operating Officer, Chief Financial Officer and General Counsel at Threshold Pharmaceuticals. From 1997 to 2004, Mr. Ostrach was at Kosan Biosciences, most recently as President and Chief Operating Officer. Mr. Ostrach began his corporate career at Cetus Corporation, where he served in several capacities between 1981 and 1991, initially as general counsel and finally as Senior Vice President of corporate affairs and General Counsel. Following the acquisition of Cetus by Chiron Corporation in 1991, Mr. Ostrach became President of Chiron Technologies. He holds a B.A. from Brown University and a J.D. from Stanford Law School. |
David Happel |
Mr. David Happel has been appointed as Vice President - Global Sales and Marketing of Dynavax Technologies Corp., effective July 10, 2012. Mr. Happel joins Dynavax from Dr. Reddy's, where he focused on building a proprietary products business for North America. Prior to Dr. Reddy's, Mr. Happel served as the Executive Vice President and Chief Commercial Officer at Aerovance. Previously at Chiron Corporation, he held leadership positions as Vice President and Global Commercial Director in the pulmonary business unit of the biopharmaceuticals division overseeing the commercialization of TOBI(R). Mr. Happel was also with InterMune, Inc. as Senior Director, Sales and Marketing where he built the commercial organization from the ground up and directed all aspects of a start-up biotech company for the commercial development of Actimmune(R). Earlier in his career he held positions with Parke-Davis/Pfizer (Warner-Lambert). Mr. Happel received his B.A. in Chemistry from Indiana University and an M.B.A. in Marketing from Indiana State University. |
Dino Dina |
Dr. Dino Dina, M.D., is Director of Dynavax Technologies Corporation. Dr. Dina has been a member of Board since May 1997 and Chief Executive Officer since May 1998. From May 1997 to June 2010, Dr. Dina was also president. From 1982 until he joined the company in 1997, Dr. Dina was an employee of Chiron Corporation, a pharmaceutical company. At Chiron, Dr. Dina held a series of positions with increasing responsibility. He ultimately served as president of Chiron Vaccines (formerly Biocine Company), which he directed from its inception in 1987. Under Dr. Dina’s direction, Chiron Vaccines received the first-ever approval of an adjuvanted influenza vaccine in Italy, completed development of the first genetically engineered pertussis vaccine and conducted clinical trials for vaccines to prevent HIV, herpes simplex type II, cytomegalovirus and hepatitis B infections. The virology group he directed was responsible for several key scientific findings, including the discovery, cloning and sequencing of the hepatitis C virus, and the cloning and sequencing of the viral genomes for HIV and hepatitis A viruses. Prior to joining Chiron, Dr. Dina was employed at Albert Einstein College of Medicine in Bronx, New York, as an assistant professor of genetics from 1977 to 1982. He received his M.D. from the University of Genoa Medical School in Italy. |
Francis Cano |
Dr. Francis R. Cano, Ph.D., serves as an Independent Director of Dynavax Technologies Corporation since November 2009. Dr. Cano is President and Founder of Cano Biotech Corp., a consulting firm focusing on the vaccine business and also serves on the boards of Biomerica, Inc., a developer and manufacturer of diagnostic products, and Arbor Vita Corporation, a biopharmaceutical company. From 1993 to 1996, Dr. Cano was President and Chief Operating Officer for Aviron, a biopharmaceutical company, which was later acquired by MedImmune in 2001. As a Co-Founder of Aviron, he completed two rounds of venture financing, a licensing agreement with SmithKline Biologicals and in-licensed Flu-Mist influenza vaccine from the National Institutes of Health. For 21 years, Dr. Cano worked with the Lederle Laboratories Division of American Cyanamid, most recently as Vice President and General Manager of the Biologicals unit. He earned a Ph.D. in Microbiology from Pennsylvania State University, served as a Research Associate at Rutgers Institute of Microbiology, and holds a M.S. in Microbiology and a B.S. in Biology from St. John’s University. |
Dennis Carson |
Dr. Dennis A. Carson, M.D., serves as an Independent Director of Dynavax Technologies Corporation since December 1997. Dr. Carson is a noted researcher in the fields of autoimmune and immunodeficiency diseases and is co-discoverer with Dr. Eyal Raz of the immunostimulatory sequences (ISS) that form the basis of technology. He has played key roles in the founding of Vical, Inc., a gene therapy company, IDEC Pharmaceuticals, a biopharmaceutical company, and Triangle Pharmaceuticals, a pharmaceutical company. Dr. Carson is a director of Biomerica, Inc. Dr. Carson is director of the Rebecca and John Moores Cancer Center at the University of California, San Diego and has been a professor in the Department of Medicine at the University of California, San Diego since 1990. He is a member of the National Academy of Sciences, the American Academy of Arts and Sciences, and the Institute of Medicine, as well as the American Association for Cancer Research, the American Society for Clinical Investigation, the American Society of Hematology and the Association of American Physicians. He received his M.D. from Columbia University and his B.A. from Haverford College. Dr. Carson completed his residency in internal medicine and a postdoctoral fellowship at the University of California, San Diego. |
Denise Gilbert |
Dr. Denise M. Gilbert, Ph.D., serves as an Independent Director of Dynavax Technologies Corporation since March 2004. From 2001 to 2002, she served as Chief Executive Officer of Entigen Corporation, a private life science information technology company. From 1995 to 1999, Dr. Gilbert served as Chief Financial Officer and Executive Vice President of Incyte Pharmaceuticals (now Incyte Corporation), a genomic technologies company, and from 1993 to 1995, she was Chief Financial Officer and Executive Vice President of Affymax, a biopharmaceutical company. From 1986 through 1993, Dr. Gilbert was a Managing Director and senior biotechnology analyst at Smith Barney Harris & Upham and Vice President and biotechnology analyst at Montgomery Securities. Dr. Gilbert is also the Chairperson of the Audit Committee of the Board, or the Audit Committee, and the Audit Committee financial expert. Dr. Gilbert serves on the board of Cytokinetics, Inc., a public biopharmaceutical company, and KaloBios Pharmaceuticals, Inc., a private company. Dr. Gilbert holds a B.S. from Cornell University and a Ph.D. in Cell and Developmental Biology from Harvard University. |
Daniel Kisner |
Dr. Daniel L. Kisner, M.D., serves as an Independent Director of Dynavax Technologies Corporation since July 22, 2010. Dr. Kisner served as a Partner at Aberdare Ventures and prior to that as President and CEO of Caliper Technologies, its evolution from a start-up focused on microfluidic lab-on-a-chip technology to a publicly-traded, commercial organization. Prior to Caliper, he was the President and COO of Isis Pharmaceuticals, Inc. Previously, Dr. Kisner was Division Vice President of Pharmaceutical Development for Abbott Laboratories and Vice President of Clinical Research and Development at SmithKline Beckman Pharmaceuticals. In addition, he held a tenured position in the Division of Oncology at the University of Texas, San Antonio School of Medicine and is certified by the American Board of Internal Medicine in Internal Medicine and Medical Oncology. Dr. Kisner serves as Chairman of the Board for Tekmira Pharmaceuticals, and he sits on the boards of several private companies. He holds a BA from Rutgers University and an M.D. from Georgetown University. He is a Venture Partner at Aberdare Ventures, a San Francisco, CA-based venture capital firm. |
Peggy Phillips |
Ms. Peggy V. Phillips serves as an Independent Director of Dynavax Technologies Corporation since August 2006. Ms. Phillips currently also serves on the board of directors of Portola Pharmaceuticals, a biopharmaceutical company, and she served on the board of Western Wireless, a cellular network operator, from 2004 until the acquisition by Alltel in mid-2005. From 2003 until 2011, Ms. Phillips served on the Board of the Naval Academy Foundation. From 1996 until 2002, she served on the board of directors of Immunex Corporation, a biotechnology company, and from 1999 she served as the Chief Operating Officer until the company was acquired by Amgen in 2002. During her career at Immunex, she held positions of increasing responsibility in research, development, manufacturing, sales and marketing. As senior vice president for pharmaceutical development and general manager for Enbrel®, she was responsible for clinical development and regulatory affairs as well as the launch, sales and marketing of the product. Prior to joining Immunex, Ms. Phillips worked at Miles Laboratories. Ms. Phillips holds a B.S. and a M.S. in microbiology from the University of Idaho. |
Stanley Plotkin |
Dr. Stanley A. Plotkin, M.D., serves as an Independent Director of Dynavax Technologies Corporation since August 2005. Dr. Plotkin is Emeritus Professor of the University of Pennsylvania. Until 1991, he was Professor of Pediatrics and Microbiology at the University of Pennsylvania and Professor of Virology at the Wistar Institute, and at the same time, Director of Infectious Diseases and Senior Physician at the Children’s Hospital of Philadelphia. In 1991, Dr. Plotkin left the University to join the vaccine manufacturer Pasteur-Mérieux-Connaught (today, Sanofi Pasteur), where for seven years he was Medical and Scientific Director, based at Marnes-la-Coquette, outside Paris. Until 2011, he was an Executive Advisor to Sanofi Pasteur. Dr. Plotkin’s career included internship at Cleveland Metropolitan General Hospital, residency in pediatrics at the Children’s Hospital of Philadelphia and the Hospital for Sick Children in London and three years in the Epidemic Intelligence Service of the Centers for Disease Control of the U.S. Public Health Service. He has been chairman of the Infectious Diseases Committee and the AIDS Task Force of the American Academy of Pediatrics, liaison member of the Advisory Committee on Immunization Practices and Chairman of the Microbiology and Infectious Diseases Research Committee of the National Institutes of Health. |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
Arnold Oronsky |
-- |
J. Tyler Martin |
2,155,720 |
Eddie Gray |
-- |
Zbigniew Janowicz |
477,785 |
David Novack |
-- |
Jennifer Lew |
1,172,650 |
Robert Coffman |
1,274,030 |
Michael Ostrach |
1,199,860 |
David Happel |
-- |
Dino Dina |
2,787,650 |
Francis Cano |
-- |
Dennis Carson |
-- |
Denise Gilbert |
-- |
Daniel Kisner |
-- |
Peggy Phillips |
-- |
Stanley Plotkin |
-- |
As Of 30 Dec 2011
Options Compensation
| Name | Options | Value |
|---|---|---|
Arnold Oronsky |
0 | 0 |
J. Tyler Martin |
0 | 0 |
Eddie Gray |
0 | 0 |
Zbigniew Janowicz |
0 | 0 |
David Novack |
0 | 0 |
Jennifer Lew |
0 | 0 |
Robert Coffman |
141,666 | 217,220 |
Michael Ostrach |
0 | 0 |
David Happel |
0 | 0 |
Dino Dina |
649,997 | 725,996 |
Francis Cano |
0 | 0 |
Dennis Carson |
0 | 0 |
Denise Gilbert |
0 | 0 |
Daniel Kisner |
0 | 0 |
Peggy Phillips |
0 | 0 |
Stanley Plotkin |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
TUCK STEPHEN F |
50,000 | $1.50 |
TUCK STEPHEN F |
24,672 | $3.04 |
COFFMAN ROBERT L |
19,926 | $1.50 |
COFFMAN ROBERT L |
10,451 | $2.86 |
MARTIN J TYLER |
35,759 | $1.58 |
COFFMAN ROBERT L |
8,000 | $1.50 |
COFFMAN ROBERT L |
8,000 | $4.31 |
KESSEL MARK A |
6,000,000 | $4.73 |
COFFMAN ROBERT L |
3,111 | $4.96 |
COFFMAN ROBERT L |
695 | $4.86 |
COFFMAN ROBERT L |
3,333 | $4.96 |
COFFMAN ROBERT L |
2,251 | $1.50 |
COFFMAN ROBERT L |
1,556 | $4.86 |
TUCK STEPHEN F |
27,510 | $4.81 |
TUCK STEPHEN F |
75,000 | $0.00 |
LEW JENNIFER |
18,750 | $4.53 |
LEW JENNIFER |
18,750 | $0.54 |
COFFMAN ROBERT L |
8,000 | $4.52 |
COFFMAN ROBERT L |
8,000 | $4.11 |
COFFMAN ROBERT L |
8,000 | $4.06 |
COFFMAN ROBERT L |
8,000 | $4.13 |
COFFMAN ROBERT L |
18,000 | $5.08 |
OSTRACH MICHAEL S |
37,505 | $0.54 |
OSTRACH MICHAEL S |
11,052 | $5.16 |
OSTRACH MICHAEL S |
23,275 | $1.58 |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
